Anti-Cancer

POMALIDOMIDE (BDPOMA) Tablet

Name: POMALIDOMIDE (BDPOMA) Tablet
Brand: variable
Availability: InStock

$207.00

However, its use requires careful oversight by hematologists or oncologists, with vigilant monitoring for adverse effects and therapeutic response. With ongoing research and clinical advancements, Pomalidomide continues to transform the treatment landscape for individuals affected by multiple myeloma, providing hope and healing in the face of adversity.

Sku:

N/A

Tag:

POMALIDOMIDE BDPOMA

Description

Pomalidomide (BDPOMA) Tablet is an oral medication used in the treatment of certain hematological malignancies, particularly multiple myeloma. It belongs to the class of immunomodulatory drugs (IMiDs) and exerts its therapeutic effects by modulating the immune system and inhibiting the growth of cancer cells.

Key Features:

Immunomodulatory Agent: Pomalidomide acts as an immunomodulatory drug, exerting multiple effects on the immune system, including enhancing T cell and natural killer (NK) cell activity, inhibiting cytokine production, and altering the tumor microenvironment. These immunomodulatory effects contribute to its antitumor activity.
Treatment of Multiple Myeloma: Pomalidomide (BDPOMA) Tablet is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including lenalidomide and a proteasome inhibitor. It offers a targeted treatment option for patients with this challenging-to-treat hematological malignancy.
Oral Administration: Pomalidomide (BDPOMA) Tablet is administered orally, typically once daily, with or without food. The convenient dosing regimen enhances patient compliance and adherence to treatment.
Multiple Mechanisms of Action: Pomalidomide exerts its antitumor effects through multiple mechanisms, including direct cytotoxicity against cancer cells, inhibition of angiogenesis, and modulation of the tumor microenvironment. These diverse mechanisms contribute to its efficacy in the treatment of multiple myeloma.
Efficacy: Clinical trials have demonstrated the efficacy of pomalidomide in prolonging progression-free survival and overall survival in patients with relapsed or refractory multiple myeloma. It has shown activity even in patients who have become refractory to other treatments, providing a valuable therapeutic option in this setting.
Safety Profile: Pomalidomide generally has a manageable safety profile when used as directed. However, like all medications, it may be associated with certain side effects, including myelosuppression (e.g., neutropenia, thrombocytopenia), fatigue, infections, and gastrointestinal disturbances. Patients should be closely monitored for adverse reactions during treatment.
Patient Education: Patients prescribed Pomalidomide (BDPOMA) Tablet should receive comprehensive education regarding proper medication administration, potential side effects, and the importance of adherence to treatment. This empowers patients to actively participate in their healthcare management and optimize therapeutic outcomes.
Consultation with Healthcare Provider: Treatment with Pomalidomide (BDPOMA) Tablet should be initiated and monitored by a qualified hematologist or oncologist experienced in the management of multiple myeloma. Close monitoring and regular follow-up are essential to ensure optimal therapeutic response and patient safety.
Access and Affordability: Efforts should be made to ensure equitable access to Pomalidomide (BDPOMA) Tablet for eligible patients, including exploring financial assistance programs and insurance coverage options to mitigate any financial barriers to treatment. Access to innovative therapies like pomalidomide is crucial for improving outcomes and quality of life for patients with relapsed or refractory multiple myeloma.